If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Kisunla ™ (donanemab-azbt) injection, for intravenous infusion
350 mg/20 mL (17.5 mg/mL)
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Should the starting dose of Kisunla™ (donanemab-azbt) be adjusted for amyloid level?
The recommended dose of Kisunla (donanemab) is not dependent on baseline amyloid levels, however evidence of Alzheimer's disease neuropathology is required.
See important safety information, including boxed warning, in the attached prescribing information.
Dosing is Not Dependent on Baseline Amyloid Levels
Donanemab is indicated for the treatment of Alzheimer's disease (AD). Treatment with donanemab should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of disease.1
Confirm the presence of amyloid beta pathology prior to initiating treatment.1
There are no dosing recommendations based on baseline amyloid level in the donanemab product labeling.1
Donanemab is administered every 4 weeks as an intravenous infusion over approximately 30 minutes with the recommended dosage and dosing schedule as described in (Donanemab Dosage and Dosing Schedule).1
Intravenous Infusiona |
Dosage |
Interval |
Infusion 1 |
350 mg |
Q4W |
Infusion 2 |
700 mg |
Q4W |
Infusion 3 |
1050 mg |
Q4W |
Infusion 4 and beyond |
1400 mg |
Q4Wb |
Abbreviations: IV = intravenous; Q4W = every 4 weeks.
aIf an infusion is missed, resume administration every 4 weeks at the scheduled dose.
bDoses are administered via IV infusion every 4 weeks and at least 21 days apart.
Enclosed Prescribing Information
References
1Kisunla [package insert]. Indianapolis, IN: Eli Lilly and Company; 2025.
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: November 14, 2025